FibroBiologics (NASDAQ:FBLG) Insider Hamid Khoja Buys 30,000 Shares

FibroBiologics Inc. (NASDAQ:FBLG) insider Hamid Khoja purchased 30,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 4th. The stock was bought at an average cost of $0.38 per share, for a total transaction of $11,400.00. Following the purchase, the insider owned 61,250 shares in the company, valued at $23,275. This represents a 96.00% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

FibroBiologics Stock Performance

NASDAQ FBLG traded up $0.01 during trading hours on Friday, reaching $0.43. 484,558 shares of the company’s stock were exchanged, compared to its average volume of 1,392,710. The company has a market capitalization of $29.09 million, a price-to-earnings ratio of -1.02 and a beta of -0.69. The company’s 50-day moving average is $0.30 and its two-hundred day moving average is $0.38. FibroBiologics Inc. has a one year low of $0.22 and a one year high of $1.53.

FibroBiologics (NASDAQ:FBLG) last announced its quarterly earnings results on Tuesday, February 24th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.06. Research analysts predict that FibroBiologics Inc. will post -0.53 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have commented on FBLG shares. D. Boral Capital decreased their price objective on shares of FibroBiologics from $15.00 to $7.00 and set a “buy” rating for the company in a report on Wednesday, February 25th. HC Wainwright cut their price objective on FibroBiologics to $4.00 and set a “buy” rating on the stock in a research report on Thursday, February 26th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of FibroBiologics in a research report on Thursday, January 22nd. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $5.50.

Institutional Investors Weigh In On FibroBiologics

A number of institutional investors have recently modified their holdings of the stock. AQR Capital Management LLC purchased a new stake in FibroBiologics in the first quarter worth approximately $29,000. XTX Topco Ltd lifted its holdings in FibroBiologics by 160.0% in the second quarter. XTX Topco Ltd now owns 45,945 shares of the company’s stock valued at $29,000 after acquiring an additional 28,276 shares during the period. Ethos Financial Group LLC raised its stake in shares of FibroBiologics by 100.0% in the second quarter. Ethos Financial Group LLC now owns 48,848 shares of the company’s stock worth $30,000 after buying an additional 24,424 shares during the period. AMG National Trust Bank purchased a new position in FibroBiologics in the 4th quarter worth approximately $31,000. Finally, Jane Street Group LLC bought a new position in FibroBiologics in the 4th quarter worth approximately $34,000.

FibroBiologics Company Profile

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc was incorporated in 2021 and is based in Houston, Texas.